Dual specific phosphatase 12 ameliorates cardiac hypertrophy in response to pressure overload

被引:17
|
作者
Li, Wei-ming [1 ]
Zhao, Yi-fan [1 ]
Zhu, Guo-fu [1 ]
Peng, Wen-hui [1 ]
Zhu, Meng-yun [1 ]
Yu, Xue-jing [1 ]
Chen, Wei [1 ]
Xu, Da-chun [1 ]
Xu, Ya-wei [1 ]
机构
[1] Tongji Univ, Shanghai Peoples Hosp 10, Dept Cardiol, Sch Med, Shanghai 200072, Peoples R China
基金
中国国家自然科学基金;
关键词
cardiac hypertrophy; dual specific phosphatase 12; c-Jun N-terminal kinase (JNK); signalling pathway; SP600125; N-TERMINAL KINASE; HEART-FAILURE; ACTIVATION; REGULATORS; CARDIOMYOPATHY; IDENTIFICATION; APOPTOSIS; REVEALS; BINDING; ERK1/2;
D O I
10.1042/CS20160664
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Pathological cardiac hypertrophy is an independent risk factor of heart failure. However, we still lack effective methods to reverse cardiac hypertrophy. DUSP12 is a member of the dual specific phosphatase (DUSP) family, which is characterized by its DUSP activity to dephosphorylate both tyrosine and serine/threonine residues on one substrate. Some DUSPs have been identified as being involved in the regulation of cardiac hypertrophy. However, the role of DUSP12 during pathological cardiac hypertrophy is still unclear. In the present study, we observed a significant decrease in DUSP12 expression in hypertrophic hearts and cardiomyocytes. Using a genetic loss-of-function murine model, we demonstrated that DUSP12 deficiency apparently aggravated pressure overload-induced cardiac hypertrophy and fibrosis as well as impaired cardiac function, whereas cardiac-specific overexpression of DUPS12 was capable of reversing this hypertrophic and fibrotic phenotype and improving contractile function. Furthermore, we demonstrated that JNK1/2 activity but neither ERK1/2 nor p38 activity was increased in the DUSP12 deficient group and decreased in the DUSP12 overexpression group both in vitro and in vivo under hypertrophic stress conditions. Pharmacological inhibition of JNK1/2 activity (SP600125) is capable of reversing the hypertrophic phenotype in DUSP12 knockout (KO) mice. DUSP12 protects against pathological cardiac hypertrophy and related pathologies. This regulatory role of DUSP12 is primarily through c-Jun N-terminal kinase (JNK) inhibition. DUSP12 could be a promising therapeutic target of pathological cardiac hypertrophy. DUSP12 is down-regulated in hypertrophic hearts. An absence of DUSP12 aggravated cardiac hypertrophy, whereas cardiomyocyte-specific DUSP12 overexpression can alleviate this hypertrophic phenotype with improved cardiac function. Further study demonstrated that DUSP12 inhibited JNK activity to attenuate pathological cardiac hypertrophy.
引用
收藏
页码:141 / 154
页数:14
相关论文
共 50 条
  • [11] Oleanonic acid ameliorates pressure overload-induced cardiac hypertrophy in rats: The role of PKCζ-NF-κB pathway
    Gao, Hui
    Liu, Hui
    Tang, Tiexin
    Huang, Xiaofei
    Wang, Dongxiu
    Li, Yan
    Huan, Pan
    Peng, Yingfu
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2018, 470 : 259 - 268
  • [12] Peroxiredoxin-1 ameliorates pressure overload-induced cardiac hypertrophy and fibrosis
    Tang, Chaoliang
    Yin, Guobing
    Huang, Chunxia
    Wang, Hongtao
    Gao, Jie
    Luo, Jianfeng
    Zhang, Zhetao
    Wang, Jiawu
    Hong, Junmou
    Chai, Xiaoqing
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 129
  • [13] Beneficial Effect of Silymarin in Pressure Overload Induced Experimental Cardiac Hypertrophy
    Sharma, Basant
    Chaube, Udit
    Patel, Bhoomika M.
    CARDIOVASCULAR TOXICOLOGY, 2019, 19 (01) : 23 - 35
  • [14] Cucurbitacin B Protects Against Pressure Overload Induced Cardiac Hypertrophy
    Xiao, Yang
    Yang, Zheng
    Wu, Qing-Qing
    Jiang, Xiao-Han
    Yuan, Yuan
    Chang, Wei
    Bian, Zhou Yan
    Zhu, Jin Xiu
    Tang, Qi-Zhu
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2017, 118 (11) : 3899 - 3910
  • [15] Autophagy and pressure overload-induced cardiac hypertrophy
    Zeng, Yong
    Ren, Wei-Qiong
    Wen, Ai-Zhen
    Zhang, Wen
    Fan, Fu-Yuan
    Chen, Ou-Ying
    JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH, 2022, 24 (12) : 1101 - 1108
  • [16] Signalling pathways in pressure-overload cardiac hypertrophy
    Peivandi, A. A.
    Loeffelholz, K.
    Vahl, C. F.
    ZEITSCHRIFT FUR HERZ THORAX UND GEFASSCHIRURGIE, 2009, 23 (01): : 9 - 16
  • [17] Effects of enalapril in rats with pressure overload cardiac hypertrophy
    Eugenio, DD
    Pietro, G
    Rosario, M
    DeSarro, G
    GENERAL PHARMACOLOGY, 1997, 28 (04): : 531 - 533
  • [18] Semaglutide ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome
    He, Wenxiu
    Wei, Jiahe
    Liu, Xing
    Zhang, Zhongyin
    Huang, Rongjie
    Jiang, Zhiyuan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [19] Rictor/mTORC2 is a Critical Mediator of Cardiac Hypertrophy and Survival in Response to Pressure Overload
    Sciarretta, Sebastiano
    Zhai, Peiyong
    Sadoshima, Junichi
    CIRCULATION, 2010, 122 (21)
  • [20] Apigenin inhibits pressure overload-induced cardiac hypertrophy
    Dong, Xuan
    Zhou, Heng
    Zhang, Yan
    Xu, Man
    Hao, Yarong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (04): : 3772 - 3778